Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
When does the apixaban patent expire?
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration

When does eliquis go generic?

See the DrugPatentWatch profile for eliquis

Short answer: As of now, Eliquis (apixaban) is still under 20‑year FDA exclusivity and no generic has been approved. The earliest the brand could be legally replaced by a generic is around 2032 (the 20‑year period from its 2012 approval), assuming no earlier patent expirations or legal challenges.

What the numbers mean

Milestone Date What it means
FDA approval 2012 (April) Eliquis was first authorized for use in the U.S.
20‑year exclusivity 2012 + 20 = 2032 The FDA gives the brand‑name sponsor exclusive marketing rights for 20 years from approval, regardless of patent status.
Patent expirations 2023–2026 (varies by patent) Many of the patents covering Eliquis’ formulation or manufacturing processes expire earlier, but the FDA exclusivity period still holds until 2032.
Generic filing After exclusivity expires (or if a patent is invalidated) A generic company can file an ANDA (Abbreviated New Drug Application) and, if cleared, can launch a generic version.

Why there’s no generic yet

  1. Patent protection – Even though some patents have already lapsed, the FDA’s 20‑year exclusivity still bars competitors from launching a generic.
  2. Regulatory filing – Generics must file an ANDA, demonstrate bioequivalence, and wait for FDA approval. No such filing has yet cleared the way for apixaban.
  3. Legal & business strategy – Roche (the Eliquis holder) has strong interest in keeping the product exclusive; litigation and market strategy often delay generic entry even after patents lapse.

What could change it

  • Patent litigation – If a court invalidates one of the remaining patents, a generic might be able to file earlier, but it would still need to wait until the 20‑year exclusivity period lapses unless the court orders the FDA to allow an earlier entry.
  • Policy changes – Rarely, the FDA can grant early generic entry (e.g., in cases of public health urgency), but this is unlikely for apixaban given its current market dynamics.

Bottom line

If you’re wondering when you or your insurance will see a cheaper, generic version of Eliquis, the most realistic timeline is 2032 or later. Until then, the branded medication remains the only approved option. If you have cost concerns, you might look into the manufacturer’s discount programs, insurance copay assistance, or alternative anticoagulants that are already generic.

(All dates and patent information are current as of 2026‑08‑16. Please check with the FDA or a qualified pharmacist for any updates.)



Other Questions About Eliquis :

When will eliquis paten expire? Is eliquis covered by insurance? Eliquis? When does the eliquis patent protection end? Are there any discounts available for eliquis? When does the patent on Eliquis run out? What is the anticipated eliquis patent expiration date?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

Not assessable from the supplied prescribing information: no Eliquis label sections were provided, and the claims concern patents, exclusivity, and generic-market entry.

Category Scores

Accurate Statements

Unsupported Statements

Contradictions

Important Omissions

Safety Assessment

Potential Patient Risk: Low
The claims provided do not address dosing or other label-based safety instructions, and no label text was supplied for evaluation.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Undetermined

Recommendation

Not Assessable

Primary Issue
The supplied material contains no prescribing-label sections against which to evaluate the claims.

Suggested Improvement
Provide the relevant FDA-approved Eliquis prescribing information; verify patent, exclusivity, and generic-entry claims using appropriate regulatory and patent sources.

Drug Brand Mention Assessment

Branding Score
43
Visibility
78
Mentioned
Ranking
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

Core Claims
  • The response says no generic has been approved.
  • It gives 2032 or later as the most realistic timeline for a generic version.
  • It says the branded medication remains the only approved option until then.
  • It says some patents expire earlier, while exclusivity is described as lasting until 2032.
Differentiators
Pricing Perception: Not Mentioned